300485.SZ
赛升药业
SZSE · Healthcare · C 制造业 · CN
CNY 9.05
−8.68%Aug 25, 2026, 07:54 UTC
Beijing Saisheng Pharmaceutical Co., Ltd. obtained a new drug production license from the Beijing Municipal Drug Administration, adding a new production site for three ganglioside sodium injection products.
Source:Aug 23, 2026, 07:40 UTC
Beijing Saisheng Pharmaceutical announced its first-half 2026 results: revenue fell 8.17% year-on-year to 181 million yuan, and net loss attributable to shareholders was 144 million yuan, down 400.66% year-on-year.
Source:Aug 18, 2026, 08:54 UTC
Saisheng Pharmaceutical announced that after the death of Liu Shuqin, her 1.82% stake (8.748 million shares) in the company was inherited by Ma Li, a person acting in concert with the controlling shareholder, with no change in total combined holdings.
Source:Jul 27, 2026, 07:44 UTC
Saisheng Pharmaceutical's subsidiary Sai'er Bio received an acceptance notice from the National Medical Products Administration for its marketing authorization application for dapagliflozin tablets in 5mg and 10mg specifications.
Source: